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Background. Vaccine development in human Plasmodium falciparum malaria has been hampered by the
exceptionally high levels of CD81 T cells required for efficacy. Use of potently immunogenic human
adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immunity to
human adenoviruses.
Methods. From 2007 to 2010, we undertook a phase I dose and route finding study of a new malaria vaccine,
a replication-incompetent chimpanzee adenovirus 63 (ChAd63) encoding the preerythrocytic insert multiple epitope
thrombospondin-related adhesion protein (ME-TRAP; n 5 54 vaccinees) administered alone (n 5 28) or with
a modified vaccinia virus Ankara (MVA) ME-TRAP booster immunization 8 weeks later (n 5 26). We observed an
excellent safety profile. High levels of TRAP antigen–specific CD81 and CD41 T cells, as detected by interferon c
enzyme-linked immunospot assay and flow cytometry, were induced by intramuscular ChAd63 ME-TRAP
immunization at doses of 5 3 1010 viral particles and above. Subsequent administration of MVA ME-TRAP boosted
responses to exceptionally high levels, and responses were maintained for up to 30 months postvaccination.
Conclusions. The ChAd63 chimpanzee adenovirus vector appears safe and highly immunogenic, providing
a viable alternative to human adenoviruses as vaccine vectors for human use.
Clinical Trials Registration. NCT00890019.
The induction of potent cellular immunity remains
a central difficulty in vaccinology. Malaria is a disease
widely regarded as an important potential target
of improved T-cell–inducing vaccines. A method of
immunoprophylaxis, such as a vaccine, would offer
a valuable tool against both the morbidity and mortality
caused by malaria [1]. Immunization of mice with irra-
diated sporozoites of murine Plasmodium falciparum
provides protection against later challenge with murine
malaria, and by transferring the CD81 T lymphocyte
clones specific to malaria surface antigens nonimmune
mice can be protected [2–4]. High-level protective CD81
T-cell responses can be induced by many vaccine types in
small animals, but despite numerous attempts, there is
no clear demonstration of the induction of very potent
CD81 T-cell responses in humans [5–7]. In animal
models, such high levels are often required to induce
protective immunity [8].
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Of the vaccination approaches assessed for induction of cel-
lular immunity in humans, adenoviral vectors and heterologous
prime-boost approaches have shown the most promise [9]. A
series of phase I/IIa clinical studies at the University of Oxford
have assessed prime-boost immunization strategies in healthy,
malaria-naive adult human volunteers using plasmid DNA and
the poxviruses modified vaccinia virus Ankara (MVA) and FP9
as vectors [7]. The most protective antigenic insert tested in
these vectors was the T-cell multiple epitope string fused to the
thrombospondin-related adhesion protein (ME-TRAP), which
was more protective than the circumsporozoite protein or
a polyprotein insert [7]. TRAP is a surface protein from the
sporozoite stage of P. falciparum [10]. Several immunization
regimes using these vectors with the ME-TRAP insert led to
statistically significant delays in time to patent parasitemia,
reflecting 80%–92% reductions in liver-stage parasite numbers
emerging from the liver after experimental malaria infections
[11]. However, these regimes induced predominantly CD41
T-cell responses, and although T-cell responses correlated with
vaccine efficacy, these approaches failed to induce protective
immunity in the majority of vaccinees, suggesting a need for
more potent vectors such as adenoviruses.
Adenoviral vectors suffered a setback with the failed hu-
man immunodeficiency virus type 1 (HIV-1) STEP vaccine
trial, which showed a lack of efficacy and a nonsignificant
trend toward increased HIV-1 infection in vaccinees [12].
However, antigen-specific responses in that trial were only of
the order of 300 spot-forming cells (SFC) per million pe-
ripheral blood mononuclear cells (PBMCs), probably in part
explaining the lack of efficacy. Moreover, the possibility
that antivector immunity might have contributed to the
suggested safety concern in the STEP trial has led to
renewed interest in the use of nonhuman adenoviral vectors
for several diseases [7].
Estimates suggest that, depending on the region, between
45% and 80 % of adults carry AdHu5 neutralizing antibodies
(nAb) [13]. Simian adenoviruses are not known to cause
pathological illness in humans, and the prevalence of anti-
bodies to chimpanzee-origin adenoviruses is,5% in humans
residing in the United States. Prevalence in young children in
Kenya, a target group for a malaria vaccine, is low, with only
4% of 1–6-year-old children in one study having high-titer
nAb to chimpanzee adenovirus 63 (ChAd63), compared with
23% having high-titer nAb to AdHu5 [14]. When used in
preclinical models, some simian adenoviruses showed similar
levels of immunogenicity to the very potent human adeno-
virus AdHu5. In the preclinical P. berghei model, some
simian adenoviruses were comparable to or appeared better
than AdHu5 in terms of immunogenicity and protective
efficacy; and in macaques, good T-cell immunogenicity was
observed [15, 16].
Here, to our knowledge, we report the first-in-human clinical
experience of a highly immunogenic nonhuman adenovirus
vaccine vector.
STUDY DESIGN
This was an open-label phase I dose and route finding
study from October 2007 to May 2010 to evaluate the safety
and immunogenicity of ChAd63 ME-TRAP alone, and in
a prime-boost regimen with MVAME-TRAP. Participant flow
and study design is summarized in Figure 1, and the vaccina-
tion regimens for each group are shown in Supplementary
figure 1A and 1B.
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Figure 1. CONSORT chart. Abbreviations: ChAd63, chimpanzee adenovirus; i.d., intradermal; i.m., intramuscular; MVA, modified vaccinia virus Ankara.
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The dose of ChAd63 ME-TRAP was first escalated from
1 3 108 to 5 3 1010 viral particles (vp) by the intradermal
route (groups 1–4, n 5 8 per group), then from 1 3 1010 to
2 3 1011 vp by the intramuscular route (groups 5–7, n 5 4–10
per group; see Figure 1). Within these groups, 4 volunteers
received a single immunization with ChAd63 ME-TRAP
(‘‘A’’ subgroups, n 5 28), and 4 received ChAd63 ME-TRAP
followed by MVA ME-TRAP 8 weeks later (‘‘B’’ subgroups,
n 5 20). In the highest-dose group (2 3 1011 vp, group 7),
2 volunteers were boosted with intradermal MVA ME-
TRAP 2 3 108 plaque-forming units (PFU; group 7B), and
4 volunteers were boosted with intramuscular MVA
ME-TRAP 2 3 108 PFU (group 7C).
In addition, in May 2010, all volunteers in the prime-boost
groups (n 5 26) were invited to return for a late-boosting
immunization with either ChAd63 ME-TRAP (5 3 1010 vp)
or MVA ME-TRAP (2 3 108 PFU) intramuscularly. In total,
11 of 26 eligible volunteers were screened for a third im-
munization and enrolled between June and July 2010.
This group was termed group 8. Vaccine allocation was
randomized 1:1, stratified by time interval since the last
immunization (n 5 5 ChAd63 ME-TRAP; n 5 6 MVA
ME-TRAP). Data for days 21–28 following reboost are
presented.
RESULTS
Manufacturing Yield and Genetic Stability of ChAd63 ME-TRAP
The Clinical BioManufacturing Facility at the University
of Oxford manufactured ChAd63 ME-TRAP [24] with
high yield, producing approximately 3.7 3 1014 vp from
a single-bulk cell culture preparation. This was the yield
obtained following cell lysis, disaggregation, centrifugation,
and filtration. From 2 bulk harvest lots, 12 840 doses
of ChAd63 ME-TRAP, with 1 3 1011 vp per vial, were
produced.
Genetic stability of ChAd63 ME-TRAP was tested by per-
forming 8 passages of a batch of the virus in human embryonic
kidney 293 (HEK293) cells and characterizing the resulting virus
using a combination of polymerase chain reaction (PCR) and
sequencing. No evidence of genetic instability was detected in
either the passaged material or the clinical batch used in the
clinical trial.
Safety
There were no serious adverse events. The 417 adverse events
considered possibly, probably, or definitely related to vaccina-
tion were reported up to and including 28 days post ChAd63
ME-TRAP (184 local and 233 systemic). Local adverse events
included pain, redness, swelling, scaling, itching, and warmth.
Systemic symptoms solicited using diary cards included
fever, feverishness (the sensation of fever without measurable
pyrexia), malaise, fatigue, arthralgia, myalgia, headache, and
nausea or vomiting. Over 90% of adverse events were mild in
nature. A detailed breakdown of adverse events occurring
postvaccination can be found in Supplementary figure 1G–K.
All subjects receiving ChAd63 ME-TRAP intradermally
(groups 1–4) reported a local adverse event, most commonly
redness (100%) and swelling (100%). Incidence of local ad-
verse events was lower in those receiving intramuscular
ChAd63 ME-TRAP (groups 5–7), with significantly fewer
local adverse events reported per volunteer at comparable
doses (P , .005; Figure 2A and 2B).
The most common systemic adverse events occurring were
fatigue (87% of volunteers), malaise (69%), and feverishness
(54%). In total, 69% of systemic adverse events were repor-
ted in the first 48 hours postvaccination, and 64% resolved
in this timeframe. The median number of systemic adverse
events experienced by a volunteer increased with vaccine
dose regardless of route of administration (Figure 2C). In
parallel, severity of reported systemic adverse events in-
creased as the dose of ChAd63 ME-TRAP increased. There
were 8 individual severe adverse events reported, 4 of which
(feverishness, headache, malaise, and coryzal symptoms)
occurred in the same volunteer who developed a coryzal illness
13 days postvaccination. Two other volunteers had 24 hours of
symptoms immediately post vaccination (1 subject with coryzal
symptoms and 1 with myalgia/arthralgia/feverishness).
The safety profile of MVA ME-TRAP was very similar to
that reported previously (Figure 2B and 2D) [17, 18]. The
preceding dose of ChAd63 ME-TRAP did not affect the in-
tensity or duration of adverse events post-MVA ME-TRAP
(data not shown). A similar acceptable safety profile was
observed after the reboosting immunizations.
Immunization-related laboratory adverse events resolved
in 4 of 54 volunteers following ChAd63 ME-TRAP (2 ALT
elevations [,1.5 3 upper limit of normal], 1 eosinophilia,
and grade 1 thrombocytopenia) and 1 of 26 volunteers fol-
lowing MVA ME-TRAP (grade 1 thrombocytopenia).
Immunogenicity
ELISPOT Responses
Ex vivo interferon c (IFN-c) enzyme-linked immunospot
(ELISPOT) responses to the vaccine antigen were detectable
in all groups after the priming vaccination with ChAd63
ME-TRAP (Figure 3). Unless stated otherwise, values re-
ported represent total summed responses to TRAP pools
and ME from the T9/96 P. falciparum strain. No significant
difference between doses of ChAd63 ME-TRAP administe-
red via the intramuscular and intradermal different routes
was observed (Figure 3A), so these routes were pooled for
further analysis.
Responses to ME-TRAP were detected 14 days after priming
vaccination with ChAd63, with median ELISPOT responses per
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dose group ranging from 61–915 SFC/106 PBMCs (hence SFC/
M) with priming doses between 1 3 108 and 2 3 1011 vp
(Figure 3B and 3D). Boosting with MVA ME-TRAP signifi-
cantly augmented the immunogenicity with individual re-
sponses as high as 2465 SFC/M (medians ranging from 764 to
2063 SFC/M for 1 3 108–2 3 1011 vp) 7 days post-MVA
ME-TRAP (Figure 3C and 3E). Response to the vaccine insert
could be detected in all volunteers at their final visits, with
excellent preservation of the effector immune response in the
prime-boost volunteers, with medians of 246–1294 SFC/M
across the different groups 3 months post boosting vaccina-
tion (Figure 3C).
Individual peak immune responses occurred either at
14 or 28 days post-ChAd63 ME-TRAP vaccination. Post
priming vaccination, there was a trend toward higher re-
sponses at higher doses with a significant difference in
ELISPOT response between 1 3 108 and 2 3 1011 vp
ChAd63 ME-TRAP (Figure 3F; P 5 .005 Kruskal-Wallis test,
medians ranging from 78.1–915 SFC/M). Post-MVA ME-
TRAP immune responses were maximal at day 63 with
a nonsignificant trend toward increasing responses as the
priming dose increased.
To assess changes in the breadth of TRAP-specific T-cell
responses by ELISPOT induced by both immunizations, the
number of peptide pools (total of 6) in which responses per
well were greater than a threshold of 100 SFC/M (after sub-
tracting the background response) were summed for each
individual, at every time point. Given the small number of
samples for each dose group, data for all groups were pooled.
A nonsignificant increase (Figure 3G) in the number of pos-
itive TRAP-specific peptide pools was observed following the
first immunization (D14 mean, 1.0 [95% confidence interval
{CI}, .4–1.6]), and this was significantly boosted by the
second immunization (D63 mean, 3.0 [95% CI, 2.2–3.8]
P , .001 compared with D14). This boosting effect of MVA
ME-TRAP was maintained up to D140 (mean 1.4 [95% CI,
.9–2.0] compared with D14, P , .05).
Cultured ELISPOT assay (cELISPOT) responses (Figure 3H)
were present in 7 of 8 volunteers examined at day 140 but did
not correlate significantly with peak ex vivo immune response
(Pearson correlation r 5 20.68, P 5 .2). Notably, cELISPOT
responses in group 4, with a median cELISPOT response of
6638 SFC/106 original PBMCs (interquartile range [IQR],
2901–9073) are double the highest value previously recorded
Figure 2. Adverse events. Local and systemic adverse events occurring post ChAd63 ME-TRAP (A–D ) and MVA ME-TRAP (B and D ). Median and
interquartile range number of local (A ) and systemic (C ) adverse events reported per volunteer post ChAd63 ME-TRAP at different doses and routes.
Panels B and D show percentage of volunteers reporting at least 1 local or systemic adverse event; shading indicates severity (highest severity of adverse
events reported by volunteers is presented). (*P , .05; ***P , .001; analyzed by Kruskal-Wallis test with Dunn post test.) Abbreviations: ChAd63,
chimpanzee adenovirus; i.d., intradermal; ME-TRAP, multiple epitope-thrombospondin–related adhesion protein; MVA, modified vaccinia virus Ankara.
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Figure 3. ELISPOT assays. A, Comparison of median ELISPOT responses at comparable doses via intradermal and intramuscular routes. Error bars
represent interquartile ranges (IQRs); no significant differences were observed. B and C, Median ELISPOT responses postvaccination in A groups and B
groups. D and E, Median ELISPOT responses day 14 and day 63 grouped by priming dose ChAd63 ME-TRAP; error bars represent IQRs. F, Peak median
ELISPOT response by priming dose ChAd63 ME-TRAP; error bars represent IQRs. G, Mean number of peptide pools recognized at different time points
(data for all volunteers analyzed using 1-way analysis of variance with Bonferroni post test; error bars represent standard errors of the mean. H, Cultured
ELISPOT responses compared with previous trials (data shown represents median and IQR, analyzed by Kruskal-Wallis test with Dunn post test. (*P, .05;
x-axis displays regimes used in previous clinical trials D 5 DNA ME-TRAP, F 5 FP9 ME-TRAP, M 5 MVA ME-TRAP.) Abbreviations: ChAd63,
chimpanzee adenovirus; ELISPOT, enzyme-linked immunospot; i.d., intradermal; i.m., intramuscular; ME-TRAP, multiple epitope-thrombospondin–related
adhesion protein; MVA, modified vaccinia virus Ankara; PBMCs, peripheral blood mononuclear cells; vp; viral particles.
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with a regime of DNA and MVA ME-TRAP given multiple
times, one of the most immunogenic and protective regimes we
have previously trialed (median, 2900; IQR, 140–4160) [19].
TRAP-specific antibody responses were identified by en-
zyme-linked immunosorbent assay (ELISA) in all recipients of
ChAd63, and were significantly boosted by MVA ME-TRAP
(data not shown).
Flow Cytometry
T-cell phenotypes (ie, CD41 vs CD81) and functional capacities
of vaccine-generated T-cell responses (ie, the production of
cytokines IFN-c, interleukin 2, and tumor necrosis factor a in
response to a pool of all 57 peptides spanning the TRAP antigen
were evaluated using flow cytometry. Assays were performed on
cryopreserved PBMCs from volunteers in groups 2B (n 5 2),
3B (n 5 4), and 4B (n 5 2) (Figure 4). No significant differ-
ences were observed between the different groups in terms of the
percentage of cytokine secreting cells; thus, all data were pooled
for further analysis.
Vaccination with ChAd63 ME-TRAP induced an increase
in the percentage of antigen-specific CD41 and CD81 T cells
capable of secreting cytokines of interest with responses
boosted by MVA ME-TRAP. TRAP-specific CD81 T cells
secreting IFN-c underwent an 8-fold increase between
baseline (mean, 0.014% [95% CI, 0–.033%]) and day 63
(mean, 0.12% [95% CI: 0–.167%]), P , .05). Boosting also
induced a marked expansion of polyfunctional T cells up to
140 days (Figure 4B).
Antivector Antibodies
Serum samples were examined for the presence of nAb to
ChAd63 in 50 of 54 volunteers. Initially, volunteers with any
evidence of nAb to ChAd63 were excluded for group 1; then
approval was given to allow recruitment in groups 2–6 of
subjects with nAb titer ,1:200, and group 7 was subsequently
approved for recruitment of volunteers with any nAb titer.
Figure 5B shows the time course of nAb. In total, 35 of 50
(83%) subjects had no evidence of ChAd63 nAb at day 0,
Figure 4. Flow cytometry. A, Percentage of parent populations (CD41 or CD81) secreting named cytokine over time. IFN-c responses peak 7 days post-
MVA boost with the frequency of CD81 T cells secreting IFN-c increasing significantly between baseline and D63 (P , .05, Kruskal-Wallis with Dunn
posttest correction). B, Polyfunctionality of TRAP-specific CD41 or CD81 T cells over time. T cells capable of secreting all 3 cytokines are only detected
after boosting with MVA. Abbreviations: IFN, interferon; IL, interleukin; MVA, modified vaccinia virus Ankara; TNF, tumor necrosis factor; TRAP,
thrombospondin-related adhesion protein.
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including 8 subjects receiving 1 3 108 vp ChAd63 ME-TRAP
(group 1), 4 of whom developed low levels after vaccination.
Of the remaining subjects negative for nAb at day 0, .90%
seroconverted after vaccination. ChAd63 dose correlated
with peak nAb titer (Spearman rank correlation r 5 0.54,
P , .0001; n 5 50), but no relationship was observed be-
tween baseline nAb and peak ELISPOT response (excluding
volunteers from group 1 with no baseline nAb; r 5 0.031,
P 5 .85; Figure 5C, n 5 42). In group 7, where any preex-
isting antibody titer was allowable, there was no evidence
that higher baseline nAb titer reduced peak (r 5 0.21,
P 5 .71, n 5 6) or day 140 ELISPOT response (r 5 20.51,
P 5 .30, n 5 6).
Reboosting
No serious vaccine-related adverse events were reported after
either reboosting immunization. The reactogenicity profile
of both vaccines was similar (Figure 6A).
Stratification for time since last vaccination was effective,
with a median of 236 days (IQR, 184.5–638) between last
vaccination and reboost for the ChAd63 ME-TRAP recipients
and 249 days (IQR, 172–606) for the MVA ME-TRAP recip-
ients (Figure 6B and Supplementary figure 1B). ELISPOT
responses were not significantly different prior to the reboos-
ting immunization between those reboosted with ChAd63
and MVA (P 5 .66) and for both groups, the reboosting im-
munization resulted in a significant increase from pre-reboosting
ELISPOT responses (median, 624 SFC/M; IQR, 294–839)
prior to reboosting to a median of 1315 SFC/M [IQR, 1024–
1991] at peak (P 5 .001; Figure 6C). There was no significant
difference in the peak reboost responses induced by ChAd63 or
MVA (1743 SFC/M [IQR, 994–2106] and 1280 SFC/M [IQR,
853–2060], respectively; P 5 .7). There was a correlation be-
tween reboosting interval and magnitude of the response to re-
boost by ELISPOT (Figure 6D).
Intracellular cytokine staining was performed on a subset of
reboosted volunteers (n 5 3 in each group) where cells were
available. A comparable percentage of total antigen-specific
CD81 IFN-c1 cells followed reboosting (ChAd63 median,
0.22% [range, 0–0.26%], MVA median, 0.410% [range,
0.009–0.142%], P 5 1.0; Figure 6E).
DISCUSSION
ChAd63 ME-TRAP at doses between 1 3 108 and 2 3 1011 vp
has been used safely in this study and generates high levels of
antigen-specific T cells which remain detectable for over
28 months post-MVA. Although other simian adenoviruses
have shown promise in preclinical studies, this is the first report
of the use of a nonhuman adenovirus as a vaccine vector in
humans to our knowledge.
Vectored vaccines have shown considerable promise as vac-
cine candidates due to their ease of generation, often low-cost
manufacture, and their ability to induce significant cellular
immunity. However, to date their development has been limited
by several obstacles. Some viral vectors, even within the ade-
novirus family, are much more potent than others, and only
a limited number of serotypes show good immunogenicity.
Second, for several vectors, proprietary cell lines are required for
large-scale manufacture, and these are not widely available.
Other vectors have been found to show significant genetic in-
stability when produced at large scale. Usage of HEK293 cells,
or the alternative PER.C6 cell line, facilitates easy growth of
ChAd63, thus providing a manufacturing process that can be
easily scaled up for mass production. Several thousand doses
of vaccine were produced in our manufacturing runs in
a process that is now very efficient. Finally, certain viral vec-
tors are limited by high levels of preexisting immunity in
many human populations, whereas ChAd63 has limited pre-
existing immunity in European and African populations.
In this trial, ChAd63 ME-TRAP has been shown to have
a good safety profile despite relatively stringent adverse analysis
(all adverse events occurring up to 28 days postvaccination
deemed possibly, probably, or definitely related were analyzed).
Rates and types of adverse events are comparable to ongoing
Figure 5. Antibodies. A, Median anti-ChAd63 antibody titers post-
vaccination. B, Correlation between day 0 anti-ChAd63 antibody titer and
peak enzyme-linked immunospot result (r 5 0.031, P 5 .85 by Spearman
rank correlation [95% confidence interval,2.2843 to .3400]). Abbreviation:
ChAd63, chimpanzee adenovirus.
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trials using human adenovirus 5 as a vector. In a recent phase 1
trial of a human adenovirus 5 expressing glycoprotein (GP)
from the Ebola virus species where 11 subjects received 2 3 1010
vp of vaccine, 6 moderate or severe systemic adverse events
were reported at this dose (6 of 29 total systemic adverse
events) [20]. In comparison, we report 1 moderate or severe
systemic adverse event occurring post-ChAd63 ME-TRAP at
1 3 1010 vp (1 of 29 total systemic adverse events reported)
making ChAd63 less reactogenic. Peiperl et al [21] assess
safety and maximal tolerated dose of an adenoviral vaccine
vector in volunteers without prior immunity, using a recombi-
nant replication-defective adenovirus type 5 (rAd5) vaccine
Figure 6. Reboosting. A, Local and systemic adverse events occurring post reboosting with ChAd63 ME-TRAP and MVA ME-TRAP. B, Interval between
first boosting vaccination with MVA and reboosting with either vector. Bar represents median interval for each group. C, Median enzyme-linked
immunospot (ELISPOT) responses after reboosting; peak response post-MVA reboost 1169 SFC/106 peripheral blood mononuclear cells (PBMCs), peak
response post-ChAd63 reboost 1558SFC/106 PBMCs). D, Relationship between reboosting interval and response to reboost (Spearman rank correlation
r 5 0.64, P 5 .035). E, Cytokine responses to first and second boosting vaccinations for all subjects in group 8, showing percentage of parent
population (either CD41 or CD81 T cells), secreting named cytokine. Abbreviations: ChAd63, chimpanzee adenovirus; IFN, interferon; IL, interleukin;
ME-TRAP, multiple epitope thrombospondin-related adhesion protein; MVA, modified vaccinia virus Ankara; TNF, tumor necrosis factor.
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expressing HIV-1 Gag, Pol, and multiclade Env proteins. Here,
20 volunteers received 2 3 1011 particle units of vaccine, and
systemic adverse events were assessed for the 72 hours following
vaccination. Fifteen volunteers report at least 1 moderate or
severe systemic adverse event occurring postvaccination. In
comparison, with ChAd63 ME-TRAP at the same dose, 10
volunteers were vaccinated and reported only 9 systemic ad-
verse events postvaccination as moderate or severe.
MVA ME-TRAP is a well-characterized vaccine in terms
of immunogenicity and once again is used safely in this trial.
It has now been administered to .600 healthy volunteers in
Oxford [22], The Gambia [23], and Kenya [24] without any
serious adverse events with volunteers receiving between 1
and 3 intradermal doses of vaccine (3–50 3 107 PFU per
dose), at 3- to 4-week intervals.
The prime-boost vaccination regimen with ChAd63 and
MVA ME-TRAP generated unprecedented levels of effector
T-cell responses, as measured by ex vivo IFN-c ELISPOT in
comparison to previous malaria vaccine trials with the same
antigenic insert. Responses here were both higher and dif-
ferent in quality. In contrast to average responses (at the peak
time point) of approximately 450 SFC/M [18, 25], we now
report average responses exceeding 2000 SFC/M. Second, by
flow cytometry we observe that there are at least as many
CD81 as CD41 gamma-interferon–secreting T cells induced
at the peak time points, in contrast to previous prime-boost
regimes using DNA and poxvirus-priming vectors, where
predominantly CD41 T-cell responses were induced. This
ability to induce both high-level CD81 and CD41 responses
with simian adenovirus–MVA prime-boost regimes should
broaden the potential utility of this approach.
This simian adenovirus vector used alone without an
MVA boost also compares very favorably in terms of im-
munogenicity with reports of HIV vaccine trials using the
AdHu5 vector, although different inserts prevent a definitive
comparison. Over 90% of our volunteers had detectable
ELISPOT responses 4 weeks after the priming vaccination,
and after 3 months, all subjects receiving adenovirus alone
had a detectable immune response compared with recently
reported HIV-1 vaccine trials using human adenovirus 5
expressing HIV gag (Ad5 gag), where after 3 doses of
1 3 1011 vp Ad5 gag at week 8 only 53% of volunteers had
a detectable response on ELISPOT [26].
Neutralizing antibodies to ChAd63 were induced in all
volunteers. But titers did not correlate with the level of
vaccine-induced immune response to the malaria insert,
as measured by ELISPOT, nor with the frequency or grade
of adverse events (data not shown). As discussed above,
ChAd63 nAb are rare in the general population but are clearly
detectable prior to vaccination in some individuals. It is
unclear whether this is caused by cross-reactivity to ChAd63
of antibodies induced by a closely related human adenovirus,
or by a low prevalence of ChAd63 infections in humans. In
group 7 where individuals with any titer of ChAd63 nAb
were enrolled, there was no reduction in the vaccine-induced
immune response in those with preexisting antibodies to
the vector. Moreover, volunteers could be safely reboosted
with either MVA ME-TRAP or ChAd63 ME-TRAP at
5–30 months after their first MVA immunization with no
impairment of vaccine immunogenicity, suggesting that
these viral vectors are suitable for repeated usage with such
an interval.
CONCLUSION
This phase I clinical trial has shown that simian adenoviruses
are safe when used alone or with an MVA boost with no
evidence of dose limiting toxicity. Importantly, the cellular
immunity induced to a full-length antigen by this vaccination
strategy appears significantly greater than with any previously
reported immunization regime.
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